These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 144332)

  • 1. The dissolution of human cross-linked plasma fibrin clots by the equimolar human plasmin-derived light (B) chain-streptokinase complex. The acceleration of clot lysis by pretreatment of fibrin clots with the light (B) chain.
    Summaria L; Boreisha IG; Arzadon L; Robbins KC
    Thromb Res; 1977 Sep; 11(3):377-89. PubMed ID: 144332
    [No Abstract]   [Full Text] [Related]  

  • 2. Alteration of fibrin network by activated protein C.
    Gruber A; Mori E; del Zoppo GJ; Waxman L; Griffin JH
    Blood; 1994 May; 83(9):2541-8. PubMed ID: 8167339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses.
    Summaria L; Sandesara J; Yang G; Vagher JP; Caprini JA
    Thromb Haemost; 1986 Aug; 56(1):71-9. PubMed ID: 2946093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha 2-plasmin inhibitor deficiency.
    Lipinski B; Gurewich V
    Lancet; 1979 Feb; 1(8111):329. PubMed ID: 84984
    [No Abstract]   [Full Text] [Related]  

  • 6. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.
    Liu JN; Gurewich V
    J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of various combinations of plasminogen and streptokinase on fibrinolysis.
    Gaffney PJ; Joe F; Rowe EA; Whitaker AN
    Haemostasis; 1981; 10(6):304-14. PubMed ID: 7327440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration.
    Andrew M; Brooker L; Leaker M; Paes B; Weitz J
    Thromb Haemost; 1992 Sep; 68(3):325-30. PubMed ID: 1440499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The resistance of fibrinogen and soluble fibrin monomer in blood to degradation by a potent plasminogen activator derived from cadaver limbs.
    Gurewich V; Hyde E; Lipinski B
    Blood; 1975 Oct; 46(4):555-65. PubMed ID: 126095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of efficacy of thrombolysin, streptokinase, and urokinase in a femoral vein clot model in rats.
    Cooley BC; Jones MM; Dellon AL
    Microsurgery; 1983; 4(1):1-4. PubMed ID: 6226846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots.
    Carr ME; Alving BM
    Blood Coagul Fibrinolysis; 1995 Sep; 6(6):567-73. PubMed ID: 7578900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin.
    Schaefer AV; Leslie BA; Rischke JA; Stafford AR; Fredenburgh JC; Weitz JI
    Biochemistry; 2006 Apr; 45(13):4257-65. PubMed ID: 16566600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interaction of streptokinase.plasminogen activator complex, tissue-type plasminogen activator, urokinase and their acylated derivatives with fibrin and cyanogen bromide digest of fibrinogen. Relationship to fibrinolytic potency in vitro.
    Cassels R; Fears R; Smith RA
    Biochem J; 1987 Oct; 247(2):395-400. PubMed ID: 3122725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinolysis of soluble and polymerized des-AA/des-AABB fibrin compared to fibrinogenolysis in buffer and in fibrinogen-boosted serum. Evidence that plasminogen activators are responsible for preferential degradation of polymerized fibrin.
    Brosstad F
    Thromb Res; 1979; 15(3-4):497-504. PubMed ID: 158847
    [No Abstract]   [Full Text] [Related]  

  • 15. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of vitreous clot lysis by urokinase: mode of action.
    Forrester JV; Edgar W; Millar W; Prentice CR; Williamson J
    Exp Eye Res; 1982 Jun; 34(6):895-907. PubMed ID: 6211365
    [No Abstract]   [Full Text] [Related]  

  • 17. Dissolution of thrombi by tissue plasminogen activator, urokinase and streptokinase in an artificial circulating system.
    Mattsson C; Nyberg-Arrhenius V; Wallén P
    Thromb Res; 1981 Mar; 21(6):535-45. PubMed ID: 7022741
    [No Abstract]   [Full Text] [Related]  

  • 18. An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents.
    Farrehi PM; Zhu Y; Fay WP
    J Thromb Thrombolysis; 2001 Dec; 12(3):273-81. PubMed ID: 11981110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of staphylokinase, streptokinase and tissue-type plasminogen activator on the lysis of retracted human plasma clots and fibrinolytic plasma parameters in vitro.
    Hauptmann J; Glusa E
    Blood Coagul Fibrinolysis; 1995 Sep; 6(6):579-83. PubMed ID: 7578902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rapid and sensitive 125I-fibrin solid-phase fibrinolytic assay for plasmin.
    Moroz LA; Gilmore NJ
    Blood; 1975 Oct; 46(4):543-53. PubMed ID: 126094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.